2.9. Antiplatelet drugs
See the NHSGGC Antiplatelet Guidelines for appropriate use of the following medicines. The existing guideline is available on the Clinical Guidelines store on StaffNet.
Prescribing Notes:
Aspirin enteric coated (EC) is not included in the Formulary and should not be used as the formulation does not reduce GI symptoms. If the patient experiences new gastro-intestinal symptoms, consider other contributory factors (e.g. alcohol intake or NSAID use) and then consider gastro-protection (e.g. omeprazole or lansoprazole).
Restrictions:
Restricted to use in accordance with the NHSGGC Guidelines for the Secondary Prevention of Stroke and TIA
Restrictions:
Prasugrel is restricted to specialist initiation and use in combination with aspirin for patients after percutaneous coronary intervention (PCI) in accordance with NHSGGC Guidelines for Antiplatelet Therapy in the Secondary Prevention of Coronary Heart Disease (in development).
Prescribing Notes:
- Prasugrel is indicated for six months post-PCI in the vast majority of cases, with duration ultimately at PCI operator discretion
- SMC has only evaluated and approved the use of the 10mg dose of prasugrel
Restrictions:
Ticagrelor, co-administered with aspirin is restricted to specialist initiation for the prevention of atherothrombotic events in selected patient groups.
A patient/GP information leaflet is available.
Prescribing Notes:
Use in combination with aspirin for the prevention of atherothrombotic events in adults with a history of myocardial infarction and a high-risk of developing an atherothrombotic event is not recommended by SMC and is non-Formulary.